Pharmaceutical compositions and methods are described for the treatment of Viral Infections, Hypercholesterolemia, hypertriglyceridemia, Alzheimers disease, Prion Diseases, and Duchenne Muscular Dystrophy with chelates of Oligonucleotides.Claim 6: pharmaceutical formulation of any of claims 1 - 5, where the oligonucleotides chelate is prepared with a divalent metal cation. Claim 1: pharmaceutical formulation of any of claims 1 - 5, where the oligonucleotides comprising Calcium and magnesium chelate.Claim 12: pharmaceutical formulation of any of claims 1 - 5, where this chelate oligonucleotides comprising at least a double stranded oligonucleotide. Claim 13: pharmaceutical formulation of any of claims 1 - 5, where this chelate oligonucleotides comprising at least one with at least one link of oligonucleotide phosphorothioate.Claim 15: pharmaceutical formulation of any of claims 1 - 5, where this chelate oligonucleotides comprising at least an oligonucleotide with a modified ribose in position 2.Claim 16: pharmaceutical formulation of any of claims 1 - 5, where this chelate oligonucleotides comprising at least an oligonucleotide that has each ribose in position 2 or methylated.Claim 18: pharmaceutical formulation of any of claims 1 - 5, where this chelate oligonucleotides comprising at least one oligonucleotide, where each is 5metilcitosina cytosine. Claim 21: a Pharmaceutical formulation comprising a chelate comprising SEQ ID no. 20 for the treatment of hypercholesterolemia.Claim 22: a Pharmaceutical formulation comprising a chelate comprising SEQ ID no. 19 for the treatment of Duchenne Muscular Dystrophy. Claim 23: a Pharmaceutical formulation comprising a chelate comprising SEQ ID no. 7 for the treatment of hepatitis C infection.Claim 24: pharmaceutical formulation of any of claims 1 - 5 and 21 - 23, where the chelate of oligonucleotides is a formula for Subcutaneous Administration. Claim 25: pharmaceutical formulation of any of claims 1 - 5 and 21 - 23, where the
